全文获取类型
收费全文 | 18313篇 |
免费 | 1337篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 176篇 |
儿科学 | 632篇 |
妇产科学 | 500篇 |
基础医学 | 2500篇 |
口腔科学 | 195篇 |
临床医学 | 2200篇 |
内科学 | 3420篇 |
皮肤病学 | 323篇 |
神经病学 | 1922篇 |
特种医学 | 492篇 |
外国民族医学 | 5篇 |
外科学 | 1967篇 |
综合类 | 138篇 |
一般理论 | 14篇 |
预防医学 | 2246篇 |
眼科学 | 269篇 |
药学 | 1190篇 |
中国医学 | 13篇 |
肿瘤学 | 1492篇 |
出版年
2024年 | 34篇 |
2023年 | 244篇 |
2022年 | 457篇 |
2021年 | 834篇 |
2020年 | 443篇 |
2019年 | 796篇 |
2018年 | 863篇 |
2017年 | 607篇 |
2016年 | 651篇 |
2015年 | 700篇 |
2014年 | 936篇 |
2013年 | 1078篇 |
2012年 | 1672篇 |
2011年 | 1661篇 |
2010年 | 823篇 |
2009年 | 698篇 |
2008年 | 1141篇 |
2007年 | 1126篇 |
2006年 | 1016篇 |
2005年 | 946篇 |
2004年 | 864篇 |
2003年 | 674篇 |
2002年 | 613篇 |
2001年 | 61篇 |
2000年 | 62篇 |
1999年 | 60篇 |
1998年 | 131篇 |
1997年 | 88篇 |
1996年 | 69篇 |
1995年 | 52篇 |
1994年 | 52篇 |
1993年 | 41篇 |
1992年 | 24篇 |
1991年 | 20篇 |
1990年 | 8篇 |
1989年 | 13篇 |
1988年 | 17篇 |
1987年 | 12篇 |
1986年 | 9篇 |
1985年 | 9篇 |
1984年 | 9篇 |
1983年 | 9篇 |
1982年 | 8篇 |
1981年 | 8篇 |
1980年 | 11篇 |
1978年 | 5篇 |
1977年 | 5篇 |
1976年 | 13篇 |
1973年 | 3篇 |
1972年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
81.
Hur Jinhee Smith-Warner Stephanie A. Rimm Eric B. Willett Walter C. Wu Kana Cao Yin Giovannucci Edward 《European journal of epidemiology》2021,36(3):325-333
European Journal of Epidemiology - Heavy alcohol consumption in mid-adulthood is an established risk factor of colorectal cancer (CRC). Alcohol use in early adulthood is common, but its association... 相似文献
82.
Attard Ritienne Dingli Philip Doggen Carine J. M. Cassar Karen Farrugia Rosienne Bezzina Wettinger Stephanie 《Zeitschrift fur Gesundheitswissenschaften》2021,29(3):611-624
Journal of Public Health - To determine the risk of myocardial infarction (MI) associated with pattern, frequency, and intensity of alcohol consumption, type of alcoholic beverage, and the combined... 相似文献
83.
Mark C Gillies Anne Mv Brooks Stephanie Young Bill Gillies Judy M Simpson Ivan Goldberg 《Clinical & experimental ophthalmology》1999,27(1):37-44
Purpose: The aim of the present study was to investigate the safety and potential efficacy of subconjunctival interferon-α2b (IFN-α), either alone or in combination with 5-fluorouracil (5-FU), in reducing the risk of failure of glaucoma surgery. Methods: A prospective, masked randomized phase II study was undertaken in which patients received three subconjunctival injections per week for 3–4 weeks postoperatively. Three treatments were compared: (i) IFN-α (1 × 10 6 IU per dose); (ii) 5-FU (5 mg per dose); and (iii) alternating IFN-α and 5-FU (BOTH). The primary outcome measures were: (i) rate of successful control of intra-ocular pressure without further surgery; and (ii) the incidence of side effects. Results: Fifty-seven patients undergoing glaucoma surgery with an increased risk of failure were evaluated, including 23 patients (40%) undergoing trabeculectomy combined with extracapsular cataract extraction as well as other conventional high-risk groups. With 53 patients (93%) completing 2 years follow up, there was no significant difference in success rates among the three groups. Intra-ocular pressure was controlled without further surgery in 79% of patients (95% confidence interval (CI): 61, 97%) receiving IFN-α, in 89% of patients (76, 100%) receiving 5-FU and in 89% of patients (76, 100%) receiving BOTH. Side effects were similar among the three groups. Conclusions: These results are consistent with a beneficial effect of IFN-α2b given either alone or in combination with 5-FU after glaucoma filtering surgery. However, the lack of a clear and substantial benefit over conventional anti-fibrotic therapy does not support the further clinical evaluation of these treatments. 相似文献
84.
Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. 总被引:5,自引:0,他引:5
Satu M?nnist? Stephanie A Smith-Warner Donna Spiegelman Demetrius Albanes Kristin Anderson Piet A van den Brandt James R Cerhan Graham Colditz Diane Feskanich Jo L Freudenheim Edward Giovannucci R Alexandra Goldbohm Saxon Graham Anthony B Miller Thomas E Rohan Jarmo Virtamo Walter C Willett David J Hunter 《Cancer epidemiology, biomarkers & prevention》2004,13(1):40-48
Intervention trials with supplemental beta-carotene have observed either no effect or a harmful effect on lung cancer risk. Because food composition databases for specific carotenoids have only become available recently, epidemiological evidence relating usual dietary levels of these carotenoids with lung cancer risk is limited. We analyzed the association between lung cancer risk and intakes of specific carotenoids using the primary data from seven cohort studies in North America and Europe. Carotenoid intakes were estimated from dietary questionnaires administered at baseline in each study. We calculated study-specific multivariate relative risks (RRs) and combined these using a random-effects model. The multivariate models included smoking history and other potential risk factors. During follow-up of up to 7-16 years across studies, 3,155 incident lung cancer cases were diagnosed among 399,765 participants. beta-Carotene intake was not associated with lung cancer risk (pooled multivariate RR = 0.98; 95% confidence interval, 0.87-1.11; highest versus lowest quintile). The RRs for alpha-carotene, lutein/zeaxanthin, and lycopene were also close to unity. beta-Cryptoxanthin intake was inversely associated with lung cancer risk (RR = 0.76; 95% confidence interval, 0.67-0.86; highest versus lowest quintile). These results did not change after adjustment for intakes of vitamin C (with or without supplements), folate (with or without supplements), and other carotenoids and multivitamin use. The associations generally were similar among never, past, or current smokers and by histological type. Although smoking is the strongest risk factor for lung cancer, greater intake of foods high in beta-cryptoxanthin, such as citrus fruit, may modestly lower the risk. 相似文献
85.
Grazia Arpino Stephanie J Green D Craig Allred Dannika Lew Silvana Martino C Kent Osborne Richard M Elledge 《Clinical cancer research》2004,10(17):5670-5676
PURPOSE: Preclinical data indicate that expression of the ErbB family of receptors, such as HER-2 and HER-1 (EGFR) may be involved in endocrine resistance. Evidence of resistance from clinical studies has been inconsistent. The present study examined whether HER-2 gene amplification or HER-1 expression predicted response to tamoxifen. PATIENTS AND METHODS: Three hundred and forty nine patients had estrogen receptor (ER)-positive breast cancer and received daily tamoxifen as initial therapy for advanced disease. HER-2 gene amplification, detected by fluorescence in situ hybridization, and HER-1 expression, evaluated by immunohistochemistry, was determined on 136 and 204 patients, respectively. RESULTS: HER-2 amplification was correlated with lower ER (P = 0.02), HER-1 positivity (P = 0.004), and HER-2 protein overexpression (P < 0.00001). The response rate was 56% for HER-2 non-amplified versus 47% for HER-2 amplified tumors (P = 0.38), and 58% for HER-1-negative versus 36% for HER-1-positive (P = 0.05). Time to treatment failure (TTF) was 7 months for non-amplified HER-2 tumors and 5 months (P = 0.007) for amplified HER-2 tumors, and there was a trend toward a better overall survival (OS) in patients with non-amplified HER-2 tumors (median 31 versus 25 months, respectively, P = 0.07). For positive versus negative HER-1 tumors, TTF was 4 versus 8 months (P = 0.08) and median survival was 24 versus 31 months (P = 0.41). Combining HER-1 expression and HER-2 gene status, patients with both negative HER-1 expression and non-amplified HER-2 had longer TTF (P = 0.001) and OS (P = 0.03) than if either were positive. In multivariate analysis, HER-2 was not an independent factor for TTF and OS, although HER-1 was significant for TTF only (P = 0.001). CONCLUSION: Patients with HER-2 amplification and HER-1 expression had lower ER levels and were modestly less responsive to tamoxifen, suggesting that molecular events in addition to those involving the ErbB receptors are important in determining the endocrine-resistant phenotype. 相似文献
86.
Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. 总被引:2,自引:0,他引:2
George A Mashour Pablo Hernáiz Driever Melanie Hartmann Stephanie N Drissel Tingguo Zhang Bianca Scharf Ursula Felderhoff-Müser Sadatoshi Sakuma Reinhard E Friedrich Robert L Martuza Victor Felix Mautner Andreas Kurtz 《Clinical cancer research》2004,10(17):5677-5683
PURPOSE: Neurofibromatosis type 1 (NF1) is characterized by systemic development of neurofibromas. Early clinical diagnosis can be ambiguous, and genetic diagnosis can be prohibitively difficult. Dysregulation of a number of growth factors has been suggested to be a mechanism of pathogenesis. This study was performed to assess the contribution of circulating growth factors for diffuse tumorigenesis and the diagnostic value of circulating growth factor identification in serum. EXPERIMENTAL DESIGN: The growth stimulation of neurofibroma-derived cells by serum from NF1 patients was tested, and serum growth factor levels in a cohort of NF1 patients (n = 39) between the ages of 7 and 70 years were analyzed. RESULTS: Concentrations of midkine (MK) and stem cell factor, but not epidermal growth factor, were substantially increased in serum of NF1 patients when compared with healthy controls. Within the NF1 group, MK levels increased dramatically at puberty from an average of 0.79 ng/mL in patients <18 years to 1.18 ng/mL in patients >18 years old. Stem cell factor and MK concentrations above a defined threshold in serum of NF1 patients are of diagnostic benefit for 96% of patients in the cohort tested. Furthermore, serum from NF1 patients enhanced proliferation of human neurofibroma-derived primary Schwann cells and endothelial cells substantially better than normal serum. CONCLUSIONS: Enhanced circulating growth factor levels contribute to diffuse tumorigenesis in NF1 and may provide the basis for molecular diagnosis. 相似文献
87.
G Varuni Kondagunta Beverly Drucker Lawrence Schwartz Jennifer Bacik Stephanie Marion Paul Russo Madhu Mazumdar Robert J Motzer 《Journal of clinical oncology》2004,22(18):3720-3725
PURPOSE: To assess the efficacy and toxicity of bortezomib (Velcade; Milennium Pharmaceuticals Inc, Cambridge, MA; formerly PS-341) in patients with metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS: Thirty-seven patients with metastatic RCC were treated with bortezomib. The first 25 patients enrolled onto the trial were treated with a dose of 1.5 mg/m2. The dose was decreased to 1.3 mg/m2 for the subsequent 12 patients, because more than 50% of the patients treated at the higher dose required dose reductions. Bortezomib was given by intravenous administration on a twice-weekly schedule for 2 weeks followed by 1 week without treatment until progression or unacceptable toxicity occurred. Twenty-three patients (62%) previously had undergone nephrectomy, and 19 patients (51%) had previously been treated with cytokine therapy. RESULTS: Of the 37 assessable patients, the best response was a partial response in four patients (11%; 95% CI, 3% to 25%) and stable disease in 14 patients (38%; 95% CI, 23% to 55%). The four patients with partial response experienced response durations of 8, 8+, 15+, and 20+ months. Grade 2 or 3 sensory neuropathy was present in 10 patients (53%) overall. One patient in the 1.5 mg/m2 group had grade 3 sensory neuropathy; no grade 3 sensory neuropathy was seen in the 1.3 mg/m2 group. CONCLUSION: The results of this trial suggest that bortezomib has an antitumor effect in individual patients with metastatic RCC. The small proportion of patients who achieved a partial response does not support routine use in metastatic RCC. Efforts to identify the molecular profile associated with clinical response or combination therapy with interferon alfa or other novel agents, may be considered. 相似文献
88.
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. 总被引:9,自引:0,他引:9
Stephanie Geisler Anne-Lise B?rresen-Dale Hilde Johnsen Turid Aas Jürgen Geisler Lars Andreas Akslen Gun Anker Per Eystein L?nning 《Clinical cancer research》2003,9(15):5582-5588
PURPOSE: Recent studies have found an association between certain TP53 mutations and resistance to anthracycline-based primary medical therapy in breast cancer. The purpose of this study was to investigate whether TP53 mutational status also might influence the response to a non-anthracycline-containing regimen in primary breast cancer. EXPERIMENTAL DESIGN: Thirty-five patients with locally advanced breast cancer were investigated for TP53 mutations before receiving combination chemotherapy with 5-fluorouracil (1000 mg/m(2) on days 1 and 2) and mitomycin (6 mg/m(2) on day 2), administered every 3 weeks for 2-10 cycles in the neoadjuvant setting. RESULTS: Mutations in the TP53 gene, in particular those affecting loop domains L2 or L3 of the p53 protein, were associated with lack of response to chemotherapy (i.e., increase in the diameter product of tumor lesion by >/=25%; P = 0.177 for all mutations and P = 0.006 for those affecting L2/L3 domains, respectively). No statistically significant correlation between TP53 LOH and response to therapy was seen. CONCLUSION: This study revealed a significant association between lack of response to 5-fluorouracil and mitomycin and mutations affecting the L2/L3 domains of the p53 protein. Together with our previous finding that such mutations predict resistance to weekly doxorubicin, our data suggest that mutations affecting this particular domain of the p53 protein may cause resistance to several different cytotoxic compounds applied in breast cancer treatment. 相似文献
89.
George A. Mensah Richard A. Goodman Stephanie Zaza Anthony D. Moulton Paula L. Kocher William H. Dietz Terry F. Pechacek James S. Marks 《Preventing chronic disease》2004,1(1)
Law, which is a fundamental element of effective public health policy and practice, played a crucial role in many of public health's greatest achievements of the 20th century. Still, conceptual legal frameworks for the systematic application of law to chronic disease prevention and control have not been fully recognized and used to address public health needs. Development and implementation of legal frameworks could broaden the range of effective public health strategies and provide valuable tools for the public health workforce, especially for state and local health department program managers and state and national policy makers. In an effort to expand the range of effective public health interventions, the Centers for Disease Control and Prevention will work with its partners to explore the development of systematic legal frameworks as a tool for preventing chronic diseases and addressing the growing epidemic of obesity, heart disease, stroke, and other chronic diseases and their risk factors. 相似文献
90.
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. 总被引:13,自引:0,他引:13
Matthew P Goetz David Toft Joel Reid Matthew Ames Bridget Stensgard Stephanie Safgren Araba A Adjei Jeff Sloan Pamela Atherton Vlad Vasile Sandra Salazaar Alex Adjei Gary Croghan Charles Erlichman 《Journal of clinical oncology》2005,23(6):1078-1087
PURPOSE: We determined the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLT) of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when infused on days 1, 8, and 15 of a 28-day cycle in advanced solid tumor patients. We also characterized the pharmacokinetics of 17-AAG, its effect on chaperone and client proteins, and whether cytochrome P450 (CYP) 3A5 and NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphisms affected 17-AAG disposition or toxicity. PATIENTS AND METHODS: An accelerated titration design was used. Biomarkers were measured in peripheral-blood mononuclear cells (PBMCs) at baseline and on days 1 and 15, and pharmacokinetic analysis was performed on day 1 of cycle 1. CYP3A5*3 and NQO1*2 genotypes were determined and correlated with pharmacokinetics and toxicity. RESULTS: Twenty-one patients received 52 courses at 11 dose levels. DLTs at 431 mg/m(2) were grade 3 bilirubin (n = 1), AST (n = 1), anemia (n = 1), nausea (n = 1), vomiting (n = 1), and myalgias (n = 1). No tumor responses were seen. 17-AAG consistently increased heat shock protein (Hsp) 70 levels in PBMCs. At the MTD, the clearance and half-life (t(1/2)) of 17-AAG were 11.6 L/h/m(2) and 4.15 hours, respectively; whereas the active metabolite 17-aminogeldanamycin had a t(1/2) of 7.63 hours. The CYP3A5*3 and NQO1*2 polymorphisms were not associated with 17-AAG toxicity. The CYP3A5*3 polymorphism was associated with higher 17-AAG clearance. CONCLUSION: The MTD of weekly 17-AAG is 308 mg/m(2). 17-AAG induced Hsp70 in PBMCs, indicating that Hsp90 has been affected. Further evaluation of 17-AAG is ongoing using a twice-weekly regimen, and this schedule of 17-AAG is being tested in combination with chemotherapy. 相似文献